Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Observational Study of RHINOSEDAL in Acute Nasal Obstruction

NCT: NCT07620522 · NOT_YET_RECRUITING

NCT IDNCT07620522
StatusNOT_YET_RECRUITING
Start Date2026-10-15
Completion2027-12-31
SponsorLaboratoires Elerte (INDUSTRY)
First posted
Last updated

Brief Summary

This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study evaluates the performance and safety of RHINOSEDAL in children and adults presenting with acute nasal obstruction associated with common cold, allergic or non-allergic rhinitis, or rhinosinusitis. Patients prescribed RHINOSEDAL in routine care will be followed for 6 ±1 days using patient-reported outcome measures including the NOSE score.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑